BioSpace News Archive

Policy

NIBIOHN Identifies Tissue-specific Exosome Marker Candidates from Blood

The National Institutes of Biomedical Innovation, Health and Nutrition based in Ibaraki-shi, Osaka Prefecture, has successfully catalogued more than 4,000 proteins contained in exosomes in healthy human blood.

March 22, 2022
·
2 min read
Drug Development

argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced positive topline data from the Phase 3 ADAPT-SC study evaluating subcutaneous efgartigimod for the treatment of generalized myasthenia gravis.

March 22, 2022
·
12 min read
Policy

Valbiotis is Strengthening Its Commitment to CSR by Joining the United Nations Global Compact and Applying the ISO 26000 Standard

Valbiotis is strengthening its commitment to Corporate Social Responsibility by joining the United Nations Global Compact and applying the ISO 26000 standard.

March 22, 2022
·
5 min read
FDA

FDA Approves First LAG 3 Inhibitor Antibody Opdualag For Metastatic Melanoma

Opdualag is a fixed dose combination of nivolumab (Opdivo) and relatlimab (LAG-3 inhibitor) developed by Bristol Myers Squibb. It is first LAG-3 inhibitor which has been granted approval by US FDA on March 18, 2022 for the management of patients with unresectable or metastatic melanoma.

March 22, 2022
·
4 min read
BioForest

LumiThera Announces US LIGHTSITE III Clinical Trial Meets Primary Efficacy Endpoint in Improving Vision in Dry Age-Related Macular Degeneration Subjects

LumiThera Inc. announced positive findings in its LIGHTSITE III, multi-center clinical trial in non-neovascular Age-Related Macular Degeneration subjects treated with the Valeda® Light Delivery System.

March 22, 2022
·
5 min read
Biotech Beach

MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit

MannKind Corporation announced that its Chief Scientific Officer, Thomas Hofmann, MD, PhD, will participate in the Cantor Virtual Rare Orphan Disease Summit on Tuesday, March 29, 2022 at 8:00 am.

March 22, 2022
·
1 min read
Business

Blue Water Vaccines Announces Publication in Nano Research Supporting Novel S&P Vaccine Platform Versatility

Blue Water Vaccines has exclusive, global licensing rights to Cincinnati Children’s Hospital Medical Center’s novel virus-like particle (VLP) vaccine platform.

March 22, 2022
·
5 min read
Drug Development

Ribon Therapeutics Initiates First-in-Human Phase 1 Clinical Study of RBN-3143 for the Treatment of Atopic Dermatitis

Ribon Therapeutics today announced that it initiated the healthy volunteer portion of its Phase 1, first-in-human, single ascending dose and multiple ascending dose (SAD/MAD) safety and pharmacokinetic study of RBN-3143.

March 22, 2022
·
3 min read
Genetown

KalVista Announces Publication of Additional KVD900 Data in Clinical & Experimental Allergy

KalVista Announces Publication of Additional KVD900 Data in Clinical & Experimental Allergy.

March 22, 2022
·
4 min read
Drug Development

AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant Patients

AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced the initiation of a Phase 3 registrational study of posoleucel, an allogeneic, off-the-shelf, multi-virus-specific T-cell (VST) therapy.

March 22, 2022
·
10 min read